Myostatin as a plausible biomarker for early stage of sarcopenic obesity

Ishibashi, Chisaki; Nakanishi, Kaori; Nishida, Makoto; Shinomiya, Haruki; Shinzawa, Maki; Kanayama, Daisuke; Yamamoto, Ryohei; Kudo, Takashi; Nagatomo, Izumi; Yamauchi-Takihara, Keiko

doi:https://doi.org/10.1038/s41598-024-79534-5

Myostatin as a plausible biomarker for early stage of sarcopenic obesity

Ishibashi, Chisaki; Nakanishi, Kaori; Nishida, Makoto et al.

Scientific Reports, 2024, 14, 28629

Number of Access:1,880（2025-10-24 11:55 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/99696

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
SciRep_14_28629	pdf	None	2.67 MB	41	2025.01.20

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Myostatin as a plausible biomarker for early stage of sarcopenic obesity
Creator	NRID 1000070933430 1000070933430 researchmap permalink ishibashi_c ishibashi_c Scopus Author ID 57184038400 57184038400 CreatorName Ishibashi, Chisaki
	NRID 1000010650872 1000010650872 researchmap permalink Kaori1222 Kaori1222 Scopus Author ID 43861565800 43861565800 CreatorName Nakanishi, Kaori
	NRID 1000000379273 1000000379273 researchmap permalink HaCC-n HaCC-n CreatorName Nishida, Makoto
	NRID 1000010908213 1000010908213 researchmap permalink h.shinomiya h.shinomiya CreatorName Shinomiya, Haruki
	NRID 1000030704788 1000030704788 researchmap permalink 7000009447 7000009447 Scopus Author ID 47661817400 47661817400 CreatorName Shinzawa, Maki
	NRID 1000000647886 1000000647886 researchmap permalink dkanayama dkanayama Scopus Author ID 13103149900 13103149900 CreatorName Kanayama, Daisuke
	NRID 1000000533853 1000000533853 ORCID 0000-0003-2610-9824 0000-0003-2610-9824 researchmap permalink yamamotor yamamotor Scopus Author ID 57791172700 57791172700 CreatorName Yamamoto, Ryohei
	NRID 1000010273632 1000010273632 researchmap permalink read0046469 read0046469 Scopus Author ID 55226973200 55226973200 CreatorName Kudo, Takashi
	NRID 1000010570583 1000010570583 researchmap permalink saxon-w saxon-w Scopus Author ID 13404305500 13404305500 CreatorName Nagatomo, Izumi
	NRID 1000070252640 1000070252640 researchmap permalink read0013673 read0013673 CreatorName Yamauchi-Takihara, Keiko
Subject	Metabolic diseases
	Myostatin
	Obesity
	Sarcopenia
Description	Ishibashi C., Nakanishi K., Nishida M., et al. Myostatin as a plausible biomarker for early stage of sarcopenic obesity. Scientific Reports 14, 28629 (2024); https://doi.org/10.1038/s41598-024-79534-5.
Abstract	Since sarcopenic obesity (SO) impacts negatively on our health, early detection of SO is essential. However, prevalence of SO in an apparently healthy population has not been well examined. This study aimed to elucidate the prevalence and related factors of SO in middle-aged women, and to investigate useful diagnostic criteria for SO. Body component analyses were conducted on 432 female Osaka University employees aged 30–59 during their health checkups. Healthy (H) and SO groups were defined using cutoff values of 5.7 kg/m2 for skeletal muscle mass index and 30% for percent body fat. Serum myostatin and insulin levels were additionally measured. Among 432 participants, the prevalence of SO was 6.3%. Grip strength (P < 0.0001) was lower and triglyceride (P = 0.0004) and low-density lipoprotein cholesterol (P = 0.0105) levels, and Homeostatic Model Assessment of Insulin Resistance (P = 0.0262) were higher in the SO group than in the H group. Serum myostatin levels in the SO group were lower than in the H group (3,107 pg/mL vs. 3,957 pg/mL, P = 0.0003). Myostatin levels may be suppressed in individuals with SO without any pre-existing conditions. Our diagnostic criteria for SO could reveal the risks for metabolic-related diseases and may be useful for the early detection of SO.
Publisher	Nature Research
Source Title	Scientific Reports
Volume (Issue)	14
Page	28629
Date of Issued	2024-11-19
Language	English
Handle URL	https://hdl.handle.net/11094/99696
eISSN	20452322
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1038/s41598-024-79534-5
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCTERMS.bibliographicCitation	Scientific Reports. 2024, 14, p. 28629
DC.title	Myostatin as a plausible biomarker for early stage of sarcopenic obesity
DC.creator	Ishibashi, Chisaki
	Nakanishi, Kaori
	Nishida, Makoto
	Shinomiya, Haruki
	Shinzawa, Maki
	Kanayama, Daisuke
	Yamamoto, Ryohei
	Kudo, Takashi
	Nagatomo, Izumi
	Yamauchi-Takihara, Keiko
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-11-19
DC.identifier	https://doi.org/10.1038/s41598-024-79534-5
DC.subject	Metabolic diseases
	Myostatin
	Obesity
	Sarcopenia
DC.description	Ishibashi C., Nakanishi K., Nishida M., et al. Myostatin as a plausible biomarker for early stage of sarcopenic obesity. Scientific Reports 14, 28629 (2024); https://doi.org/10.1038/s41598-024-79534-5.
DCTERMS.abstract	Since sarcopenic obesity (SO) impacts negatively on our health, early detection of SO is essential. However, prevalence of SO in an apparently healthy population has not been well examined. This study aimed to elucidate the prevalence and related factors of SO in middle-aged women, and to investigate useful diagnostic criteria for SO. Body component analyses were conducted on 432 female Osaka University employees aged 30–59 during their health checkups. Healthy (H) and SO groups were defined using cutoff values of 5.7 kg/m2 for skeletal muscle mass index and 30% for percent body fat. Serum myostatin and insulin levels were additionally measured. Among 432 participants, the prevalence of SO was 6.3%. Grip strength (P < 0.0001) was lower and triglyceride (P = 0.0004) and low-density lipoprotein cholesterol (P = 0.0105) levels, and Homeostatic Model Assessment of Insulin Resistance (P = 0.0262) were higher in the SO group than in the H group. Serum myostatin levels in the SO group were lower than in the H group (3,107 pg/mL vs. 3,957 pg/mL, P = 0.0003). Myostatin levels may be suppressed in individuals with SO without any pre-existing conditions. Our diagnostic criteria for SO could reveal the risks for metabolic-related diseases and may be useful for the early detection of SO.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	99696
citation_title	Myostatin as a plausible biomarker for early stage of sarcopenic obesity
citation_author	Ishibashi, Chisaki
	Nakanishi, Kaori
	Nishida, Makoto
	Shinomiya, Haruki
	Shinzawa, Maki
	Kanayama, Daisuke
	Yamamoto, Ryohei
	Kudo, Takashi
	Nagatomo, Izumi
	Yamauchi-Takihara, Keiko
citation_publisher	Nature Research
citation_language	English
citation_date	2024-11-19
citation_journal_title	Scientific Reports
citation_volume	14
citation_firstpage	28629
citation_doi	https://doi.org/10.1038/s41598-024-79534-5
citation_public_url	https://hdl.handle.net/11094/99696

Myostatin as a plausible biomarker for early stage of sarcopenic obesity

Link to primary information

Item Information

Show details